Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Aged Cells Retain Capacity for Rejuvenation via Enhanced Extracellular Support

By BiotechDaily International staff writers
Posted on 19 Dec 2012
Researchers have found that aged human skin fibroblasts retain their capacity for a high degree of reactivation and that this capacity can be significantly restored simply by enhancing the aged extracellular structural support.

In an independent study at the University of Michigan Medical School’s Department of Dermatology (Ann Arbor, MI, USA), scientists have succeeded in making the skin cells of senior citizens behave much like younger cells again by adding more fiber filler to the aging scaffold supporting the cells. The study gives a new perspective on the importance of the extracellular matrix (ECM) in the aging process of skin and possibly also in other types of tissue.

The dermal ECM provides strength and resiliency to skin and consists mostly of type I collagen fibrils produced by the fibroblasts. With aging, ECM collagen fragmentation results in reduced fibroblast cell function and in cell shrinkage. In the study, injection of cross-linked hyaluronic acid (a dermal filler that enhances ECM mechanical support and is commonly used to treat aging facial skin) into the buttock skin of 21 individual volunteers about 80 years of age, or into dermal-equivalent cultures, stimulated TGF-β signaling-dependent production of type I collagen and fibroblast elongation. Also observed in vivo were fibroblast proliferation, expanded vasculature, and increased epidermal thickness. Over three months, the fibroblasts showed increased expression of collagen-related genes, produced more collagen, and bound more effectively to the ECM.

“This shows that skin cells in elderly people have the capacity to respond robustly in a very positive way to alterations in the mechanical property of their environment,” said senior author Gary Fisher, PhD and Harry Helfman professor of Molecular Dermatology. “By altering the matrix using an external filler and increasing the internal pressure, we’ve shown that we can essentially trigger a signal for cells to wake up,” said Prof. Fisher. However, he cautions that the new work does not suggest that cosmetic filler should be used throughout the body. Rather, the importance of the discovery lies mainly in the potential to harness the broader understanding of the ECM for prevention and for more effective therapeutic strategies; such as in relating to skin thinning due to aging, for example, which leaves skin more prone to tearing and interferes with healing after incisions or injury.

The study was reported October 25, 2012, in the Journal of Investigative Dermatolology advance online publication.

Related Links:

University of Michigan Medical School, Dept. of Dermatology



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.